Roche enters the SERD market with FDA approval in late-stage breast cancer
Roche’s big-hope breast cancer pill giredestrant was in an odd situation in that it was awaiting two different FDA approval decisions. Also oddly, the second one came first. The drug was
November 17, 2026 07:00 AM EST PharmaFDA+ Roche enters the SERD market with FDA approval in late-stage breast cancer Elizabeth Cairns Senior biopharma journalist Roche’s big-hope breast cancer pill giredestrant was in an odd situation in that it was awaiting two different FDA approval decisions. Also oddly, the second … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that